27 November 2020 : Clinical Research
The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
Lijun Hu1ABCDEF*, Ze Kong1BCDF, Qinghong Meng1BCD, Jianlin Wang1BCF, Mengyun Zhou1BC, Jingping Yu1ACEG, Xiaodong Jiang2ACEGDOI: 10.12659/MSM.927221
Med Sci Monit 2020; 26:e927221
Table 2 Comparing the incidences of radiation esophagitis, radiation pneumonia, and bone marrow suppression between the 2 groups.
| Adverse reactions | Apatinib group (31 cases) | CCRT group (34 cases) | χ2 | P |
|---|---|---|---|---|
| Bone marrow suppression III–IV degree | 11 (35.5%) | 13 (38.2%) | 1.323 | 0.989 |
| Radiation esophagitis 3–4 degree | 14 (45.1%) | 24 (70.5%) | 4.638 | 0.071 |
| Radiation pneumonia 2–3 degree | 16 (51.6%) | 22 (64.7%) | 6.076 | 0.056 |
| Apatinib group – chemoradiotherapy plus Apatinib group; CCRT group – concurrent chemoradiotherapy only group. | ||||